rVSV-ΔG-EBOV-GP-Nipah-G(PHV02)复制 competent 重组水疱性口炎病毒疫苗预防尼帕病毒病的风险获益评估标准化模板
本文采用 Brighton Collaboration BRAVATO 标准化模板,对表达尼帕病毒 G 蛋白的 rVSV-EBOV 载体疫苗候选株 PHV02 进行风险获益评估。PHV02 是嵌合病毒,兼具野生型 VSV、rVSV-EBOV-GP 载体及 NiV G 转基因供体的特性,目前处于临床试验阶段。模板旨在为疫苗开发者和监管审评者提供参考,以理解该候选疫苗的特性、获益与风险,并与已获批的同一 rVSV 载体系统但针对不同适应症(埃博拉病毒)的疫苗进行比较。
要点
- PHV02 是基于 rVSV-EBOV 载体插入尼帕病毒 G 蛋白基因的嵌合疫苗候选株,正处于临床试验。
- EBOV GP 介导细胞膜融合与病毒进入,NiV G 蛋白介导细胞附着并作为刺激 NiV 特异性免疫的抗原。
- PHV02 从监管角度是新型构建体,靶向疾病不同,不能简单外推 rVSV-EBOV 载体的数据。
核心结论
- PHV02 是新型嵌合疫苗候选株,其风险获益评估需基于自身数据,不能仅依赖 rVSV-EBOV 载体的类比。
研究设计与样本
- 本文为综述,采用 Brighton Collaboration BRAVATO 标准化模板,对 rVSV-EBOV 载体和 PHV02 疫苗候选株的关键特征与风险进行更新。
主要发现
- PHV02 是表达尼帕病毒 G 蛋白的 rVSV-EBOV 载体疫苗候选株,目前处于临床试验阶段。
- EBOV GP 使病毒能与细胞膜融合并进入细胞,NiV G 蛋白介导细胞附着并作为 NiV 特异性免疫的抗原。
- PHV02 是嵌合病毒,其嗜性和免疫学特性源自野生型 VSV 亲本、rVSV-EBOV-GP 载体和 NiV G 转基因供体。
关键数值与推荐
- 标准化模板旨在为疫苗开发者和监管审评者提供 cohesive 参考,以理解 PHV02 的特性、获益与风险,并与已获批的 rVSV-EBOV 疫苗进行比较。
- 在将 rVSV-EBOV 载体与 PHV02 的非临床和临床结果进行类比时,应认识到这些结论的局限性。
临床怎么用
- 疫苗开发者和监管审评者可利用该模板理解 PHV02 的特性、获益与风险,并与其同一载体系统的已获批疫苗进行比较。
局限性
- PHV02 从监管角度是新型构建体,靶向疾病不同,与 rVSV-EBOV 载体的类比结论存在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A recombinant vesicular stomatitis virus (rVSV) expressing the glycoprotein (GP) of Ebola virus (rVSV-EBOV GP) has been approved for preventive immunization against Ebola (Ervebo®, Merck & Co.). The rVSV-EBOV vector was modified to express an additional glycoprotein (G) of Nipah virus (NiV), a bat-borne henipavirus endemic/epidemic in South and Southeast Asia that causes fatal encephalitis and pneumonia. The rVSV-EBOV-GP-NiV G vaccine candidate ("PHV02") is a unique chimeric virus with tropism and immunological properties derived from the wild-type (wt) vesicular stomatitis virus (VSV) parent, the rVSV-EBOV-GP vector and the NiV G transgene donor. The EBOV GP enables fusion with the cell membrane and virus entry, whereas the NiV G protein mediates attachment to cells and serves as the antigen for stimulating NiV-specific immunity. This review focuses on the characteristics of the vector and vaccine candidate relevant to clinical and environmental safety, immunogenicity and efficacy. The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) standardized template is used to update the key characteristics and risks of the rVSV-EBOV vector (previously published [1]) and the novel PHV02 NiV vaccine candidate which is now in clinical trials. The template provides a rich source of information and guide to the supporting literature. While analogies of the PHV02 NiV vaccine to the backbone rVSV-EBOV vector are useful given the more extensive data available on the vector, the template emphasizes that PHV02 is a novel construct from a regulatory perspective and targets a different disease with unique characteristics and pathogenesis. Where similarities and parallels are drawn between nonclinical and clinical outcomes of rVSV-EBOV (vector) and PHV02 (vaccine), the reader should be cognizant of the limitations of these conclusions. The intended use of the standardized template is to provide a cohesive reference allowing vaccine developers and regulatory reviewers to understand characteristics, benefits and risks of a new vaccine candidate against NiV relevant to its future use in human populations, and to compare and contrast these characteristics to an approved vaccine constructed from the same (rVSV) vector system against a different indication (ebolavirus). The systematized template structure should facilitate utility of the paper.
引用
- Monath TP, Fusco J, Erbelding E, et al. rVSV-ΔG-EBOV-GP-Nipah-G (also designated PHV02) replication-competent, recombinant vesicular stomatitis virus vaccine for prevention of Nipah virus disease: Standardized template with key considerations for a risk/benefit assessment. Vaccine. 2026. PMID: 42869683. doi:10.1016/j.vaccine.2026.129113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。